Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • toowan12 toowan12 Jun 26, 2010 8:06 AM Flag

    IBD article on second reading...interesting

    http://finance.yahoo.com/news/Clinical-Trial-Results-Affect-ibd-3986201698.html?x=0&.v=1

    First read seems negative but closer reading shows how politically important Hematide is:

    "Its latest trial data, released last Monday, show that Hematide is no less effective than existing biologic drugs from Amgen in stimulating production of red blood cells. In other words, no advantage."

    Ah, well how about much lower cost?

    "Hematide would be beneficial because it would be one step toward finding a lower-cost alternative," Buhr said. Lower cost is something the Centers for Medicare and Medicaid Services, the federal agency that pays for most dialysis, is demanding.

    Bingo!!!!!

    Read a little further and one can see how much $$ is spent on dialysis drugs - OMG! No wonder Hematide is so highly regarded. The economics are no small factor and if the trials show Hema "no less effective" but WAY LESS EXPENSIVE and the existing drug costs are killing the countrys budget something's got to give. Hematide in dialysis patients is golden with same effectivity as epogen and much lower dosing requirements and lower cost.

 
AFFY
0.0750.0000(0.00%)Jul 1 11:35 AMEDT